Back to Results
First PageMeta Content
Pharmacy / Clinical research / Pharmaceutical industry / Research and development / James Love / Agreement on Trade-Related Aspects of Intellectual Property Rights / Food and Drug Administration / Patent / Health Impact Fund / Pharmaceutical sciences / Pharmacology / Intellectual property law


Comment– Make Drugs Affordable: Replace TRIPs-plus by R&D-plus James Love and Tim Hubbard The global trade framework for financing new medical technologies is in trouble. It will and should change. If we want innovati
Add to Reading List

Document Date: 2011-10-06 19:15:46

Open Document

File Size: 47,88 KB

Share Result on Facebook

City

Cambridgeshire / /

Company

Korea Herald / Ford / Medline / Washington Post / /

Continent

Europe / /

Country

Germany / Switzerland / Thailand / Turkey / France / Japan / United States / Italy / Dominican Republic / Korea / United Kingdom / /

Currency

USD / /

Facility

Wellcome Trust Sanger Institute / /

IndustryTerm

finance mechanisms / medical technologies / insurance / insurance premiums / non-innovative copycat products / foreign pharmaceutical / pharmaceutical / technology transfer / /

MedicalCondition

cancer / malaria / SARS / neglected diseases / heart disease / Bird Flu / AIDS / infectious diseases / chronic diseases / chronic asthma / /

Organization

Korean Government / National Institute of Health / U.S. Congress / Wellcome Trust Sanger Institute / International Trade Administration / US government / European Commission / WTO / FDA / European Union / Royal Society / Consumer Project / /

Person

Robert Wittes / Tim Hubbard / James Love / /

Position

research scientist / Director / executive / head of human genome analysis / unskilled worker / research scientist and former BMS executive / /

Product

Plavix / Erbitux / /

PublishedMedium

Washington Post / Korea Herald / PLoS Biology / /

Technology

drug development / Human Genome / /

URL

www.ictsd.org / /

SocialTag